National survey of UK clinical guidelines for the management of coronary heart disease, lung and breast cancer, asthma and depression

1997 ◽  
Vol 2 (4) ◽  
pp. 120-123 ◽  
Author(s):  
Françoise Cluzeau ◽  
Peter Littlejohns ◽  
Jeremy Grimshaw ◽  
Gene Feder
Keyword(s):  
Breast Cancer ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
National Survey ◽  
Clinical Guidelines

scholarly journals Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59

2020 ◽  
Author(s):  
Ross L Prentice ◽  
Aaron K Aragaki ◽  
Rowan T Chlebowski ◽  
Jacques E Rossouw ◽  
Garnet L Anderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Coronary Heart Disease ◽  
Endometrial Cancer ◽  
Heart Disease ◽  
Hip Fracture ◽  
Global Index ◽  
All Cause Mortality ◽  
Conjugated Equine Estrogens ◽  
Equine Estrogens

Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women’s Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acetate. Over an 18-year (median) follow-up period (1993-2016) risk for a global index, defined as the earliest of coronary heart disease, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, endometrial cancer, hip fracture, and all-cause mortality, is reduced with conjugated equine estrogens with hazard ratio (95% confidence interval) of 0.82 (0.71, 0.95), and with nominally significant reductions for coronary heart disease, breast cancer, hip fracture and all-cause mortality. Corresponding global index hazard ratio estimates of 1.06 (0.95, 1.19) were non-significant for combined estrogens plus progestin, but increased breast cancer risk and reduced endometrial cancer risk were observed. These results, among women 50-59, substantially agree with the worldwide observational literature, with the exception of breast cancer for estrogens alone.

Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus

2007 ◽  
Vol 30 (1) ◽  
pp. 120-127 ◽  
Author(s):  
Majidreza Kamyar ◽  
B. Julienne Johnson ◽  
John J. McAnaw ◽  
Rosa Lemmens-Gruber ◽  
Steve A. Hudson
Keyword(s):  
Diabetes Mellitus ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Guidelines ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii

scholarly journals The Impact of the Introduction of Clinical Recommendations on Cardiology in the USA and Russia Federetionon Mortality from Ischemic Heart Diseas

2018 ◽  
Vol 17 (4) ◽  
pp. 30-37
Author(s):  
A. A. Gerasimov
Keyword(s):  
United States ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Russian Federation ◽  
Clinical Guidelines ◽  
The United States ◽  
Ischemic Heart ◽  
The Russian Federation ◽  
The Impact

1 million 824 thousand people died in the Russian Federation in 2017, including 457 thousand from ischemic heart disease (IHD). IHD caused more than a quarter of deaths in Russia. Goal. The article analyzes the impact of implementation of clinical guidelines in cardiology in medical practice in the United States and the Russian Federation on the dynamics of mortality from ischemic heart disease and its outcomes in different age groups. Results. The results showed that the implementation of clinical guidelines (CG) increased the rate of mortality reduction from coronary heart diseases in Russia and the United States, which may indicate a positive impact CG on the quality of medical care. Conclusions. A higher level of mortality from coronary heart disease in Russia compared to the United States may be due to less commitment of doctors to the principles of therapy and diagnosis of various forms of coronary heart disease, set out in clinical guidelines.

National Survey of Pharmacists About Coronary Heart Disease, Hypercholesterolemia, Nonprescription Statin Therapy, and Pharmacists’ Services

2004 ◽  
Vol 44 (5) ◽  
pp. 562-568 ◽  
Author(s):  
James M. McKenney ◽  
J. Chris Bradberry ◽  
Robert L. Talbert ◽  
Edward Cahill ◽  
W. Virgil Brown
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Statin Therapy ◽  
National Survey

Color Data v2: a user-friendly, open-access database with hereditary cancer and hereditary cardiovascular conditions datasets

2020 ◽  
Author(s):  
Mark J. Berger ◽  
Hannah E. Williams ◽  
Ryan Barrett ◽  
Anjali D. Zimmer ◽  
Wendy McKennon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Atrial Fibrillation ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Open Access ◽  
Hereditary Cancer ◽  
Phenotypic Information ◽  
Open Access Database ◽  
Color Data ◽  
User Friendly

ABSTRACTPublicly-available genetic databases promote data sharing and fuel scientific discoveries for the prevention, treatment, and management of disease. In 2018, we built Color Data, a user-friendly, open access database containing genotypic and self-reported phenotypic information from 50,000 individuals who were sequenced for 30 genes associated with hereditary cancer. In a continued effort to promote access to these types of data, we launched Color Data v2, an updated version of the Color Data database. This new release includes additional clinical genetic testing results from more than 18,000 individuals who were sequenced for 30 genes associated with hereditary cardiovascular conditions, as well as polygenic risk scores for breast cancer, coronary artery disease, and atrial fibrillation. In addition, we used self-reported phenotypic information to implement the following four clinical risk models: Gail Model for five-year risk of breast cancer, Claus Model for lifetime risk of breast cancer, simple office-based Framingham Coronary Heart Disease Risk Score for ten-year risk of coronary heart disease, and CHARGE-AF simple score for five-year risk of atrial fibrillation. These new features and capabilities are highlighted through two sample queries in the database. We hope that the broad dissemination of this data will help researchers continue to explore genotype-phenotype correlations and identify novel variants for functional analysis, enabling scientific discoveries in the field of population genomics.Database URL: https://data.color.com/

Sign in / Sign up

Export Citation Format

Share Document